Diagnostics giant Roche is putting its weight behind a biomarker for Alzheimer’s disease developed by ALZpath.
The Swiss group has taken a license to use an antibody developed by ALZpath against a form of phosphorylated tau protein – pTau217 – for the development and commercialisation of a blood test for Alzheimer’s.
The Swiss group has taken a license to use an antibody developed by ALZpath against a form of phosphorylated tau protein – pTau217 – for the development and commercialisation of a blood test for Alzheimer’s.
